Exclusive Summary

• Innovative Dual Mechanism: UB697 is an innovative mAb featuring a dual mechanism of PD-1 receptor agonism and selective depletion of pathogenic T-cells, demonstrating Best-in-class potential.
• Overcoming Current Treatment Limitations: Unlike conventional immunosuppressants (TNF-α, JAK inhibitors), UB697 selectively targets pathogenic T cells without affecting total T cells, markedly reducing infection risks with no evidence of carcinogenicity.
• Excellent Phase 1 Clinical Data: Demonstrated a favorable safety profile with doses escalated up to 1600 mg, without any dose-limiting toxicities (DLTs) or SAEs, and is poised to enter Phase 2.
• Differentiated Competitive Advantage: Compared to competitors from AnaptysBio and Eli Lilly, UB697 shows superior half-life (16-17 days), optimal Fc receptor binding affinity, and ligand-enhanced depletion.
• Multibillion-Dollar Market Opportunity: Targets major autoimmune indications including Rheumatoid Arthritis, Lupus, and Sjögren's Syndrome, presenting immense value for cross-border license-out or co-development.

Asset Materials

Contact Us for Full Materials